The mission of the Viral/Molecular Core (Core D) is to provide high quality virological and molecular services, facilities, consultation and training to Penn CFAR investigators;facilitate the use of emerging and/or specialized technology;support scientific priorities of the Penn CFAR including both existing programs and emerging Scientific Working Groups (SWG);support, mentor and train the next generation of investigators;and encourage entry into HIV/AIDS research by established non-AIDS researchers. Specific Core goals are to: (1) Provide state-of-the-art virology services: the Core maintains a large virus repository, performs virus isolation from patient samples, amplifies virus stocks, performs Gag antigen ELISA quantification, and other viral services;(2) Provide state-of-the-art molecular services: the Core has established a new Single Genome Amplification (SGA) service and provides Deep Sequencing, real-time qPCR, as well as full-service molecular virology support, including a GLP-like release assay for gene therapy clinical studies;(3) Facilitate utilization of new emerging technologies and provide support for CFAR strategic priorities: In addition to the recently-introduced SGA and Deep Sequencing services, new services in the coming cycle to support CFAR initiatives include quantification of integrated viral DNA in patient samples, an inducible latent virus (lUPM) assay, and an ultrasensitive viral load assay. (4) Provide education and training: the Core will continue to provide training in virological and molecular techniques as well as consultation and experimental design support for optimal application of new services;(5) Provide mentoring and facilitate cross-disciplinary outreach: The Core is heavily invested in mentoring/support of junior investigators, and outreach to bring non-HIV/AIDS investigators into HIV/AIDS research. In the current cycle, the Core has offered a wide array of heavily used services, introduced major new technologies, and provided support to 98 individual investigators and 147 projects that generated $740,500 in chargebacks. The Core provided extensive mentorship for emerging junior investigators, training/education for students, postdocs and other laboratory personnel, engaged multiple investigators in other fields to focus on HIV/AIDS research, and worked closely with other Cores of the CFAR to achieve collaborative goals. These efforts will continue in the coming cycle, along with additional major new services to support new research priorities.

Public Health Relevance

The Viral/Molecular Core (Core D) adds value to the Penn CFAR and its research mission by offering specialized services, reagents and materials;training, education and technology to enhance research skills and capacity;and mentoring and outreach to expand the pool of investigators working in the field, which together enhance the capacity for cutting edge research dedicated to the prevention, treatment and cure of HIV/AIDS and its complications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI045008-16
Application #
8697307
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
16
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Gowda, Charitha; Lott, Stephen; Grigorian, Matthew et al. (2018) Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study. Open Forum Infect Dis 5:ofy076
Clarke, Erik L; Connell, A Jesse; Six, Emmanuelle et al. (2018) T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency. Genome Med 10:70
Coviello, D M; Lovato, R; Apostol, K et al. (2018) Prevalence of HIV Viral Load Suppression Among Psychiatric Inpatients with Comorbid Substance Use Disorders. Community Ment Health J :
Martei, Yehoda M; Pace, Lydia E; Brock, Jane E et al. (2018) Breast Cancer in Low- and Middle-Income Countries: Why We Need Pathology Capability to Solve This Challenge. Clin Lab Med 38:161-173
Ojikutu, Bisola O; Bogart, Laura M; Higgins-Biddle, Molly et al. (2018) Facilitators and Barriers to Pre-Exposure Prophylaxis (PrEP) Use Among Black Individuals in the United States: Results from the National Survey on HIV in the Black Community (NSHBC). AIDS Behav 22:3576-3587
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Wood, Sarah; Ratcliffe, Sarah; Gowda, Charitha et al. (2018) Impact of insurance coverage on HIV transmission potential among antiretroviral therapy-treated youth living with HIV. AIDS 32:895-902
Shin, S S; Modongo, C; Zetola, N M et al. (2018) High rates of exposure to tuberculosis patients among HIV-infected health care workers in Botswana. Int J Tuberc Lung Dis 22:366-370
Genn, Leah; Chapman, Jennifer; Okatch, Harriet et al. (2018) Pharmacy Refill Data are Poor Predictors of Virologic Treatment Outcomes in Adolescents with HIV in Botswana. AIDS Behav :

Showing the most recent 10 out of 775 publications